Globe Newswire

Form 8.5 (EPT/RI) - Centaur Media May 2, 2024 02:37AM

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader:Investec Bank plc(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offereeCentaur... (continue reading...)

Form 8.5 (EPT/RI) - Renalytix Plc May 2, 2024 02:36AM

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader:Investec Bank plc(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offereeRenalytix... (continue reading...)

Green Hydrogen Systems announces issuance of warrants to executive management and key employees May 2, 2024 02:29AM

Company announcement 12/2024

Green Hydrogen Systems announces issuance of warrants to executive management and key employees

Kolding, Denmark, 1 May 2024 – Green Hydrogen Systems A/S (“Company”) announces the decision to issue warrants for executive management and key employees, who are in a non-terminated position and who were employed on 1 April 2024. The warrant program is established as a long-term incentive scheme reflecting the Company’s... (continue reading...)

Medigene Presents Superior TCR-T Cell Functionality by Inclusion of a Costimulatory Switch Protein May 2, 2024 02:30AM

Planegg/Martinsried, May 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, presented superior T cell receptor engineered T (TCR-T) cell functionality upon combination of optimal affinity 3S (sensitive, specific and safe) TCRs with the PD1-41BB costimulatory switch protein (CSP) at the 7th International Neoantigen Summit... (continue reading...)

Medigene Presents Superior TCR-T Cell Functionality by Inclusion of a Costimulatory Switch Protein May 2, 2024 02:30AM

Planegg/Martinsried, May 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, presented superior T cell receptor engineered T (TCR-T) cell functionality upon combination of optimal affinity 3S (sensitive, specific and safe) TCRs with the PD1-41BB costimulatory switch protein (CSP) at the 7th International Neoantigen Summit... (continue reading...)